Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous monocyte-derived DCs pulsed with EBV antigen
- Development stage
- Phase 1
- Lead developer
- Hengsai Biologics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
KSD-101 is an investigational autologous dendritic cell (DC) vaccine developed by Tongji Hospital for the treatment of Epstein-Barr virus (EBV)-associated malignancies, including haematologic neoplasms, nasopharyngeal carcinoma, and lymphomas. The therapy is produced by deriving dendritic cells from a patient's own monocytes and pulsing them with lysates from EBV-transformed B-lymphoblastoid cell lines (B-LCL). These lysates provide a broad spectrum of EBV-specific antigens, which the dendritic cells present to the patient's immune system. The primary mechanism of action is the activation and expansion of EBV-specific cytotoxic T lymphocytes (CTLs) that can specifically recognize and eliminate EBV-infected tumor cells. Early clinical results have shown high response rates in patients with relapsed or refractory EBV-associated diseases.
- Other names
- autologous monocyte-derived dendritic cells pulsed with EBV antigenEBV-antigen pulsed DC vaccine
02
Targets
TLR9 (Toll-like receptor 9)TNFRSF9 (CD137 extracellular domain)CD28 (Cluster of Differentiation 28)TCR (T-cell receptor)
Beyond the preview
Go deeper on autologous monocyte-derived DCs pulsed with EBV antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous monocyte-derived DCs pulsed with EBV antigen.